Nelmastobart clinical trials
How each study uses nelmastobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nelmastobart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- hSTC810
- 1
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
STCube, Inc. (5) · Korea University Anam Hospital (1)
Often tested with
Tested in the same studies.
Trifluridine tipiracil drug combination (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test nelmastobart.
- Aug 2027Nelmastobart in Combination With Docetaxel in Non Small Cell Lung CancerPhase 2 · STCube, Inc.
Studies
Open first, then newest update. How each study uses nelmastobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Nelmastobart in Combination With Docetaxel in Non Small Cell Lung CancerRecruitingPhase 2STCube, Inc.NCT07306624Written as Nelmastobart and Docetaxel
- Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal CancerNot yet recruitingPhase 1STCube, Inc.NCT07656038Written as Nelmastobart in combination with TAS-102 and Bevacizumab
- Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal CancerRecruitingPhase 1/2STCube, Inc.NCT06873763Written as Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab
- Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal CancerActive, not recruitingPhase 1/2Korea University Anam HospitalNCT05990543Written as Nelmastobart and Capecitabine
- A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung CancerTerminatedPhase 1/2STCube, Inc.NCT06016270Written as hSTC810 400 mg + Paclitaxel
- A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)CompletedPhase 1STCube, Inc.NCT05231746Written as hSTC810
Codes
What other systems call nelmastobart · ClinicalTrials.gg INT014524
- UNII (FDA) 2S69ME4B3RNELMASTOBARTOne source FDA
- NCI Thesaurus C190185NelmastobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2S69ME4B3R | NELMASTOBART | One source FDA |
| NCI Thesaurus | C190185 | Nelmastobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.